Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC

Condition:   Non-small Cell Lung Cancer Interventions:   Drug: Anlotinib Plus Docetaxel;   Drug: Docetaxel Sponsor:   First Affiliated Hospital of Guangxi Medical University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials